Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK.
Department of Urology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore.
World J Urol. 2019 Feb;37(2):367-372. doi: 10.1007/s00345-018-2386-4. Epub 2018 Jun 22.
We report the perioperative outcomes and complications after transition from extracorporeal urinary diversion (ECUD) to intracorporeal urinary diversion (ICUD) following robot-assisted radical cystectomy (RARC).
Analysis of data from a prospectively maintained institutional review board-approved database of 180 patients treated with cystectomy at our institution from April 2015 to October 2017 was performed. 127 patients underwent RARC and received an ileal conduit. Only five patients received a neobladder after RARC and were excluded from analysis.
68 patients had extracorporeal and 59 intracorporeal ileal conduit after RARC. There were no significant differences in patient demographics and oncological characteristics between the two groups. Of note, intracorporeal ileal conduit was associated with significantly reduced median total operative times (330 vs 375 min, p = 0.019), reduced median estimated blood loss (300 vs 425 ml, p < 0.035) and lower 30-day overall complication rates (48.4 vs 71.4%, p = 0.008) when compared to extracorporeal diversion. However, the median length of stay, 30-90-day complication rates, mortality rates and ureteroileal anastomotic stricture rates were similar in both groups. The median operative time for RARC and intracorporeal ileal conduit was significantly shorter in the second cohort of 29 cases compared to the first 30 cases (300 vs 360 min, p = 0.004). Other outcomes were similar in both cohorts.
In our experience, transition from extracorporeal to intracorporeal diversion after RARC is safe, technically feasible and benefits from shorter operative times, reduced estimated blood loss, and lower 30-day overall complication rates.
我们报告了在机器人辅助根治性膀胱切除术(RARC)后从体外尿路转流(ECUD)转为体内尿路转流(ICUD)的围手术期结果和并发症。
对我院 2015 年 4 月至 2017 年 10 月接受膀胱切除术的 180 例患者的前瞻性维护机构审查委员会批准的数据库进行了分析。127 例患者接受了 RARC 并接受了回肠造口术。只有 5 例患者在 RARC 后接受了新膀胱并被排除在分析之外。
68 例患者在 RARC 后行体外回肠造口术,59 例患者行体内回肠造口术。两组患者的人口统计学和肿瘤特征无显著差异。值得注意的是,与体外引流相比,体内回肠造口术与显著缩短的中位总手术时间(330 与 375 分钟,p=0.019)、中位估计失血量(300 与 425 毫升,p<0.035)和降低的 30 天总并发症发生率(48.4 与 71.4%,p=0.008)相关。然而,两组的中位住院时间、30-90 天并发症发生率、死亡率和输尿管-回肠吻合口狭窄发生率相似。与前 30 例相比,第 29 例的 RARC 和体内回肠造口术的中位手术时间明显缩短(300 与 360 分钟,p=0.004)。两组其他结果相似。
根据我们的经验,在 RARC 后从体外转为体内转流是安全的,技术上可行的,并且具有手术时间更短、估计失血量减少和降低 30 天总并发症发生率的优势。